基因工程α-2a干扰素治疗带状疱疹临床观察

Clinical Trial of Recombinant Alpha-2a Interferon in the Treatment of Herpes Zoster

目的 为了了解α-2a干扰素(因特芬)治疗带状疱疹的疗效和不良反应,应用因特芬治疗带状疤疹,并与对照组进行比较。方法 74例带状疱疹患者,分为因特芬治疗组和对照组,因特芬治疗组44例,每日肌肉注射因特芬100万单位,疗程6d;对照组30例,维生素B_1 10mg,每日三次口服,维生素B_(12) 100μg,每日一次肌肉注射,疗程6d。结果 无新起水疱天数两组间无显著差异(P>0.05),开始结痴天数,止痛天数,治愈天数及全病程天数两组间均有非常显著差异(P<0.01)。治疗组无后遗神经痛,对照组9例有后遗神经痛,两组间无显著差异。治疗组4例发生不良反应,对照组未见不良反应,两组间无显著差异。结论 因特芬能缩短带状疱疹的病程,减轻症状,值得临床用于治疗带状疱疹。

Objective A clinical trial on 74 patients with herpes zoster was conducted to observe the efficacy and side effects of recombinant alpha-2a interferon. Methods All patients were divided into two groups, including forty-four patients in interferon-treated group and 30 patients in controlled group. The interferon-treated group was treated with i. m. recombinant alpha-2a-interferon in a daily dose of one million unit for 6 days. The controlled group was treated with vitamin B_(12) and vitamin B_1 in conventional dose for 6 days. Results The duration of scarring, pain relieving, cure and course of disease in interferon-treated group was significantly shorter than that in controlled group (P<0.01). There was no postherpetic neuralgia in interferon-treated group and there were postherpetic neuralgia in 9 cases of controlled group (P>0.05). Side effects were mild in interferon-treated group. Conclusions It seems that recombinant alpha-2a-interferon may be recommended as a good medicine for herpes zoster.